Trial Profile
A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ajinomoto Pharma; Takeda
- 07 Feb 2017 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 07 Feb 2017 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 05 Mar 2014 New source identified and integrated ClinicalTrials.gov record (NCT02066376) (it is a duplicate record)